

Circulating fibrocytes are increased in children and young adults with pulmonary hypertension

M.E. Yeager*', C.M. Nguyen*, D.D. Belchenko*, K.L. Colvin[§], S. Takatsuki[#], D.D. Ivy[§] and K.R. Stenmark*',

ABSTRACT: Chronic inflammation is an important component of the fibroproliferative changes that characterise pulmonary hypertensive vasculopathy. Fibrocytes contribute to tissue remodelling in settings of chronic inflammation, including animal models of pulmonary hypertension (PH). We sought to determine whether circulating fibrocytes were increased in children and young adults with PH.

26 individuals with PH and 10 with normal cardiac anatomy were studied. Fresh blood was analysed by flow cytometry for fibrocytes expressing CD45 and procollagen. Fibrocyte numbers were correlated to clinical and haemodynamic parameters, and circulating CC chemokine ligand (CCL)2 and CXC chemokine ligand (CXCL)12 levels.

We found an enrichment of circulating fibrocytes among those with PH. No differences in fibrocytes were observed among those with idiopathic *versus* secondary PH. Higher fibrocytes correlated to increasing mean pulmonary artery pressure and age, but not to length or type of treatment. Immunofluorescence analysis confirmed flow sorting specificity. Differences in plasma levels of CCL2 or CXCL12, which could mobilise fibrocytes from the bone marrow, were not found.

We conclude that circulating fibrocytes are significantly increased in individuals with PH compared with controls. We speculate that these cells might play important roles in vascular remodelling in children and young adults with pulmonary hypertension.

KEYWORDS: Fluorescence-activated cell sorting, inflammation, mononuclear phagocyte, progenitor cells, vascular remodelling

hronic pulmonary hypertension (PH) is distinguished by cellular and structural changes in the walls of pulmonary arteries. Intimal thickening and fibrosis, medial hypertrophy and fibroproliferative changes in the adventitia are common [1]. In adults and children, virtually all of these changes are characterised by increased numbers of cells expressing smooth muscle *a*-actin [2] and by perivascular accumulation of inflammatory cells [3, 4]. The source of these cells remains unclear but an origin from circulating progenitors has been postulated [4, 5]. In adults, the number and differentiation capability of endothelial progenitor cells (EPCs) has been examined, though no consensus has been reached as to a role for these cells in the pathogenesis of the disease [6, 7]. There are fewer data available regarding circulating cells of any kind in children and young adults with PH. Recently, it was reported that while no significant differences in early or late EPC endothelial

colony-forming units exists between reversible and irreversible PH [8], late EPCs were found to be increased in children receiving treprostinil compared with those on endothelin receptor antagonists or phosphodiesterase inhibitors [6]. These cells had increased angiogenic and hyperproliferative potential, which was hypothesised to partly explain the clinical benefits of prostanoids in pulmonary arterial hypertension (PAH). Nevertheless, severe PH is confoundingly associated with vascular pruning in the periphery, with concomitant inflammation, hypertrophy and hyperplasia in larger bronchovascular structures [1]. Periarterial infiltrates of macrophages and T-lymphocytes have been documented in the setting of PH [9]. Within similar inflammatory infiltrates in hypoxic animals, c-kit+ progenitor cells have also been identified [10, 11]. The origin of inflammatory/progenitor cells and the mechanisms by which they contribute to the pulmonary vascular remodelling and inflammation

AFFILIATIONS

*Dept of Paediatrics, Division of Pulmonary and Critical Care Medicine, #Cardiovascular Pulmonary Research, *Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado Denver, Aurora, CO, and *The Pulmonary Hypertension Program and Section of Cardiology, Dept of Paediatrics, The University of Colorado Denver and The Children's Hospital, Denver, CO, USA.

CORRESPONDENCE

M.E. Yeager University of Colorado Denver Health Sciences 12700 E 19th Ave Box C218 Aurora C0 80045 USA E-mail: michael.yeager@ ucdenver.edu

Received: April 28 2011 Accepted after revision: June 05 2011 First published online: June 23 2011

European Respiratory Journal Print ISSN 0903-1936 Online ISSN 1399-3003

For editorial comments, see page 5.

observed in children and young adults with PH have not been thoroughly investigated.

Emerging experimental evidence indicates that circulating mesenchymal precursors may contribute significantly to vascular remodelling processes [12]. The development of vascular remodelling probably requires lung infiltration of mononuclear phagocytic cells. Depletion of circulating monocytic cells using clodronate-containing liposomes prevents PH in large and small animal models [13]. Recently, several studies have pointed to the importance of fibrocytes, a subpopulation of mononuclear phagocytes, in the development of cancer and inflammatory disorders [14]. These cells derive from haematopoietic precursor cells and promote fibrogenic and chronic inflammatory processes [15]. Fibrocytes are characterised by expression of CD45 and collagen, and are associated with poor prognosis in patients with idiopathic pulmonary fibrosis [16]. In the lung, they are recruited to sites of injury where they participate directly (by producing cytokines) or indirectly (by inducing resident cells to elicit cytokines) in persistent inflammatory remodelling and proangiogenic signalling [17]. Interestingly, use of the stable prostacyclin analogue treprostinil significantly reduced the lung recruitment of fibrocytes in hypoxic mice compared with normoxic mice [18]. Treprostinil also reduced right ventricular systolic pressure and slightly reduced vascular remodelling, but failed to reverse the right ventricular hypertrophy in these mice with hypoxic PH. This important study highlights the possibility that measurement and therapeutic targeting of circulating fibrocytes might represent a promising frontier in clinical management of PH.

Since circulating fibrocytes are elevated in adults with chronic inflammation and since chronic inflammation is associated with PH, we hypothesised that children and young adults with PH would manifest increased numbers of blood fibrocytes. The continual influx of these cells might thereby sustain a cycle of perpetual inflammation and vascular remodelling in the lung. To begin to test this, we used flow cytometry of peripheral blood to quantify the number of fibrocytes in individuals with PH undergoing treatment with a variety of agents, including prostacyclin analogues, compared with controls. We found significant increases in fibrocytes in PH blood that correlated with increasing mean pulmonary artery pressure (\bar{P}_{Pa}) and age. It is concluded that PH is associated with elevated circulating fibrocytes that might play important roles in vascular remodelling.

METHODS

Subjects and blood collection

The Colorado Multiple Institutional Review Board (University of Colorado Denver, Denver, CO, USA) approved the study, and consent and assent was obtained from all patients where appropriate. The demographic data for all subjects are presented in tables 1 and 2. 5 mL blood was drawn from the femoral vein during initial cardiac catheterisation in all patients. The PAH group consisted of children and young adults who were <18 yrs of age at time of diagnosis with PH, from World Health Organization classification group I, defined as either idiopathic PAH (IPAH), heritable PAH or PAH associated with congenital heart disease (APAH-CHD) [2]. The control group included children <18 yrs of age with a structurally normal heart undergoing heart arrhythmia ablation before the onset of the procedure. All patients undergoing ablation were in normal

sinus rhythm at the start of the catheterisation, when the blood was drawn, and had a normal echocardiogram.

Haemodynamic parameters and echocardiographic data were obtained at the time of initial catheterisation, then later at therapeutic assessment. Fresh, never-frozen blood (5 mL) was prepared without a Ficoll gradient, as described by MOELLER *et al.* [16]. Buffy coat cells were removed from blood centrifuged for 10 min at $450 \times g$ (1,200 rpm) at room temperature. Following red blood cell lysis by addition of ammonium chloride (0.15 M, pH 7.3), leukocytes were washed, verified for viability by trypan blue exclusion and prepared to a concentration of 1×10^6 cells·mL⁻¹ for antibody labelling and flow cytometry.

Flow cytometric analysis

Cells were labelled for flow cytometry using a Pacific Blueconjugated antibody against CD45 (PB986; BD Biosciences, Franklin Lakes, NJ, USA), fixed and permeabilised according to the manufacturer's protocol (Fix/Perm Solution 554714; BD Biosciences), and then cells were labelled with rabbit anti-human procollagen I (MAB1913; Millipore, Billerica, MA, USA). Secondary antibody (fluorescein isothiocyanate (FITC)-conjugated goat antirabbit immunoglobulin G; AP132F; Millipore) was applied according to the manufacturer's protocols. The negative thresholds for CD45-Pacific Blue and the FITC isotype control were set using isotype control-labelled cells from both normal and PH subjects exactly as described by MATHAI et al. [19]. All subsequent samples were gated for the CD45+ region. Data were recorded as fibrocyte numbers per millilitre of blood and as a percentage of total leukocyte (CD45+) counts. A minimum of 200,000 events was used to generate each histogram. Flow cytometry was performed on an FC500 flow cytometer using CXP software (Beckman Coulter Inc., Brea, CA, USA).

Cytospin and immunofluorescence

In separate experiments, cells were resuspended to 0.5×10^6 cells. mL⁻¹ and 200 μ L was centrifuged at 250 × g (800 rpm) for 3 min. Cytospins were fixed in ice cold 1/1 acetone/methanol for 10 min then rehydrated in phosphate buffer prior to addition of antibody. Prepared cells were stained with antibodies exactly as described earlier for flow cytometry. Antibody isotype negative controls were included with each sample group, as was preadsorption of antibody to its cognate antigen, which was supplied by the manufacturers. Slides were mounted in Vectashield plus 4',6-diamidino-2-phenylindole (DAPI) medium (Vector Laboratories Ltd, Burlingame, CA, USA). Images were acquired at room temperature using a Zeiss Axiovert S100 microscope fitted with Zeiss 20×0.4na and 10×0.3na objective lenses and an Axiocam camera (Carl Zeiss Inc., Thornwood, NY, USA). Acquisition of images was performed using Axiovision 4.6 software (Carl Zeiss Inc.). Immunopositive cells (green) were counted in five fields from three cytospin preparations each from three control preparations and three PH preparations, then divided by the total number of DAPI+ cells.

Clinical data

Charts were reviewed, and data on demographics, haemodynamics and the 6-min walk test were extracted. All information describing the patient populations is presented in tables 1 and 2.

No. No. <th>Weild Mail <</th> <th>TA</th> <th>TABLE 1</th> <th>Pulmonary</th> <th>hyperter</th> <th>Pulmonary hypertension (PH) subject data</th> <th>t data</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Weild Mail <	TA	TABLE 1	Pulmonary	hyperter	Pulmonary hypertension (PH) subject data	t data							
K KO ¹ Color K KO ¹ Color F PMH1 21 236906 1472010 27 26 2304 F PMH1 21 2369166 10 1472010 27 26 2304 F PMH1 21 2369166 10 1472010 29 125 2105 2064 F PPM12 15 21691080 10 1472010 29 125 2063 2064 F SPM12 15 21050020 10 1472010 29 21 2105 2064 F SPM12 16 21050020 17 2105 2065 2064 F SPM12 17 1002002 21 1103000 21 21 2005 2005 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006	No. No. <th></th> <th>Sex</th> <th>PH, WHO class</th> <th>Age yrs</th> <th>Date of diagnosis day/month/yr</th> <th>Р_{ра} at diagnosis mmHg</th> <th>Date of sample day/ month/yr</th> <th>P̄_{pa} at date of sample mmHg</th> <th>Fibi</th> <th>rocytes</th> <th>MCP-1 pg·mL⁻¹</th> <th>SDF-1 pg·mL⁻¹</th> <th>Medications at transition</th>		Sex	PH, WHO class	Age yrs	Date of diagnosis day/month/yr	Р _{ра} at diagnosis mmHg	Date of sample day/ month/yr	P̄ _{pa} at date of sample mmHg	Fibi	rocytes	MCP-1 pg·mL ⁻¹	SDF-1 pg·mL ⁻¹	Medications at transition
F PM41 20 722007 32 4472010 37 203 236 236 F PM42 15 2561066 NA 1472010 37 705 3763 3944 F SP442 9 2169090 NA 1472010 26 201 203 3044 F SP442 19 2169090 NA 1577010 57 749 265 2701 304 301 F SP442 19 2165002 71 2172010 57 749 265 2701 304 301	1 F FHAI 20 72900 20 700 20 200 Control transmission 2 F FHAI 21 260006 NA 472010 20 705 3064 50 Control transmission 3 F FHAI 1 260006 0 472010 20 705 2044 50 2004 50000000 50 4 F FHAI 10 21000000 50 472 20 201 5000000 50 472000 50 70 5000000 50 70 5000000 50 700 50 7000000 50 700 5000000 50 70 5000000 50 70 5000000 50 70 5000000 50 70 50000000 50 70 70000000 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70 70									%	×10 ⁶ cells·mL ⁻¹			
M PM-L2 5 289'986 NA 4772010 37 703 7034 F PM-L2 9 280'000 90 477010 29 423 0.5 2015 2014 F SPM-L2 15 216'1090 NA 157/7010 29 423 0.55 2015 2014 F SPM-L2 15 150/2002 54 157/7010 59 423 0.55 2015 2014 F SPM-L2 15 150/2002 54 157/7010 54 327 2025 2026 2026 F SPM-L3 17 100 10 11/162010 54 11/13 0.55 2026 2026 2016 F SPM-L3 17 11/162010 24 11/13 0.55 2026 2026 2016 F SPM-L3 16 11/162010 24 11/13 0.55 2026 2016 2026 2026 2026 <td>1 PMI 2 200'103 MA 4/7210 57 715 714 Statement (up, up, up, up, up, up, up, up, up, up,</td> <td>-</td> <td>ш</td> <td>IPAH, 1</td> <td>20</td> <td>7/2/2007</td> <td>32</td> <td>14/7/2010</td> <td>30</td> <td>0.9</td> <td>0.21</td> <td>218</td> <td>2360</td> <td>Ca²⁺ blocker</td>	1 PMI 2 200'103 MA 4/7210 57 715 714 Statement (up, up, up, up, up, up, up, up, up, up,	-	ш	IPAH, 1	20	7/2/2007	32	14/7/2010	30	0.9	0.21	218	2360	Ca ²⁺ blocker
F IPAH,2 9 296,005 90 4476010 28 423 055 2015 2001 201 F SMH,2 15 216/1990 NA 1577010 51 319 217 2026 317 301 M SPM,4 19 21603002 54 1577010 55 7.49 0.75 22.05 301 F SPM,3 17 2103002 54 11/82010 55 7.49 0.75 22.05 302 F SPM,1 10 71/0300 54 11/82010 54 11.3 0.75 23.05 302	3 1 6141 3 268/05/05 60 167/20/01 261 2004 Consenting (1, 1)- Marchenian 4 1 57/41 1 2014 2014 2014 2014 2014 2014 2014 4 1 57/41/3 1 2015/2000 54 157/2010 54 54/41 54/41 56/41 54/41 54/41 56/41 54/41 54/41 56/41 54/41 54/41 56/41 <th< td=""><td>N</td><td>Σ</td><td>IPAH, 2</td><td>15</td><td>25/9/1995</td><td>NA</td><td>14/7/2010</td><td>37</td><td>7.05</td><td>0.7</td><td>376.3</td><td>1394.4</td><td>Sildenafil+treprostinil (i.v.)+</td></th<>	N	Σ	IPAH, 2	15	25/9/1995	NA	14/7/2010	37	7.05	0.7	376.3	1394.4	Sildenafil+treprostinil (i.v.)+
F SPM4 IS Z15/1980 NA IS77201 S1 S2 Z2 Z2 <thz2< th=""> <thz2< th=""> <thz2< th=""></thz2<></thz2<></thz2<>	4 F SPM1 15 21631960 NA 1572010 51 3246 1371 TadathHenporisity Transform 6 M SPM1 10 21/332002 54 157201 52 749 075 21/3 TadathHenporisity Transform 6 M SPM1 10 21/332002 54 157200 52 749 075 21/3 TadathHenporisity Transform 7 F SPM1 10 21/32000 51 1573 022 2220 050000(x)- transform 7 SPM1 12 21/3000 51 1530 023 2221 2203 05000(x)- transform 11 SPM1 12 21/3000 13 13600 23 232 232 2006 16400Henprotentin 11 SPM1 12 21/3000 13 132 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006 2006	e	ш		6	29/6/2005	06	14/7/2010	28	4.23	0.55	201.5	2004	Epoprostenol (i.v.)+
W SPAH, 4 19 2103.020 51 157.2010 55 749 075 217.1 16868 F SPAH, 2 15 1506.2002 71 217.2010 51 6.74 0.65 243 2022 F SPAH, 3 17 217.0208 58 217.2010 51 6.74 0.65 243 2203 2023 F SPAH, 1 12 71 118.2010 53 113 0.65 3261 2260 M PAH, 1 12 2 2008.000 NA 118/2010 21 0.13 0.65 3261 2269 2066 M PAH, 1 12 2 2008.000 NA 118/2010 21 0.13 0.05 2321 2066	6 7.41 7.9 7.40 7.4 7.40 7.7 16.8 Tadath-sprotendia 6 7 7.9 7.41 7.9 7.43 7.43 7.44 7.4	4	ш		15	21/5/1999	NA	15/7/2010	54	3.8	0.42	242.6	1370.1	ambrisentan Tadalafil+treprostinil <i>(i.v.</i>)+
F SPAH, 2 15 1505/2002 71 217/2010 51 6.74 0.65 2.45 202 F PAH, 2 10 7/10/2008 58 21/7/2010 35 4.54 0.65 362 1308 F PAH, 3 17 6/10/3026 NA 11/8/2010 35 4.54 0.65 362 363 F SPAH, 1 12 2/17/2007 36 11/8/2010 35 6.3 0.45 363 2273 M PAH, 2 2 2 10/2007 36 11/8/2010 37 0.15 0.16 350 273 353 F SPAH, 1 15 10/8/2006 NA 11/8/2010 27 56 0.17 0.16 350 273 353 F SPAH, 1 16 1/8/2007 24 36 373 369 373 369 373 369 F SPAH, 1 16 1/8/2007 24 </th <td>6 FMA, L 15 1506,5020 71 277500 51 67.4 0.65 24.2 Tadalit-morrentin (mee) 7 F FH4, L 10 7/00002 53 17,5000 43 113 0.65 26.2 Tadalit-morrentin (mee) 9 F FM4, L 10 7/00002 54 113 0.65 36.2 Tadalit-morrentin (mee) 9 F SPM, L 12 2/1/1001 19 1138200 24 13 263 153 66 10.666////14 1 M FM1, L 5 2/000208 NA 1138200 24 21 200 56 1164814 766 766////14 766///14<td>ß</td><td>Σ</td><td></td><td>19</td><td>21/03/2002</td><td>54</td><td>15/7/2010</td><td>55</td><td>7.49</td><td>0.75</td><td>271.7</td><td>1826.8</td><td>amonsentan Tadalafil+epoprostenol (i.v.)+</td></td>	6 FMA, L 15 1506,5020 71 277500 51 67.4 0.65 24.2 Tadalit-morrentin (mee) 7 F FH4, L 10 7/00002 53 17,5000 43 113 0.65 26.2 Tadalit-morrentin (mee) 9 F FM4, L 10 7/00002 54 113 0.65 36.2 Tadalit-morrentin (mee) 9 F SPM, L 12 2/1/1001 19 1138200 24 13 263 153 66 10.666////14 1 M FM1, L 5 2/000208 NA 1138200 24 21 200 56 1164814 766 766////14 766///14 <td>ß</td> <td>Σ</td> <td></td> <td>19</td> <td>21/03/2002</td> <td>54</td> <td>15/7/2010</td> <td>55</td> <td>7.49</td> <td>0.75</td> <td>271.7</td> <td>1826.8</td> <td>amonsentan Tadalafil+epoprostenol (i.v.)+</td>	ß	Σ		19	21/03/2002	54	15/7/2010	55	7.49	0.75	271.7	1826.8	amonsentan Tadalafil+epoprostenol (i.v.)+
F PAH,2 1 7/0/2008 58 2/17/2010 35 4.54 0.56 3662 3602 3608 F SPAH,3 17 6/10/992 N 11/8/2010 35 4.54 0.55 32312 2508 F SPAH,1 12 2/17/1001 19 11/8/2010 23 6.3 0.43 353.4 2272 M PAH,1 12 2/17/1001 19 11/8/2010 23 6.3 0.43 353.4 2273 M PAH,1 12 1 2/0010 13 11/8/2010 21 15 0.13 0.35 273 1375 F SPAH,1 3 2.008/2007 NA 11/8/2010 21 16 2733 175 F SPAH,1 3 2.008/2007 NA 11/8/2010 21 16 2733 1962.2 M SPAH,1 3 2.008/2007 NA 2.868/2010 24 2.66	7 1 PHI.2 0 7/10/000 58 2/7/2010 55 454 556 362 366 10000 6 SPHI.3 17 6/0/080 NA 11/80/01 45 11/3 0.26 362 362 360 104800 7 SPHI.1 12 2/1/1/001 19 11/82/00 23 0.3 0.3 362 360 104800 1 SPHI.1 12 2/1/1/001 19 11/82/00 23 0.3 0.3 363.4 222 Chinbacio 1 PHI.1 1 1 1 0.1	9	ш		15	15/05/2002	71	21/7/2010	51	6.74	0.65	243	2022	ambrisentan Tadalafil+treprostinil
F Frant, 2 10 7/10/2008 56 2/11/2010 55 1343 1350 2321 1303 F SPAH, 1 12 2/17/1001 13 1/18/2010 35 1,13 0.05 352.1 1303 F SPAH, 1 12 2/17/1001 13 1/18/2010 23 1,13 0.05 353.4 2272 M PAH, 2 2 2/2007 NA 1/18/2010 23 1,13 0.05 353.4 2026 2043 M PAH, 1 15 2/08/2005 NA 1/18/2010 27 155 0.01 363.2 2036 F SPAH, 1 15 2/08/2005 NA 1/18/2010 27 156 0.01 363.2 2036 F SPAH, 2 13 1/10/2001 73 2/8/8/2010 24 363 2/73 1963.2 M PAH, 1 15 2/8/8/2010 24 38 1/18/2010 21	7 F WM1, 2 10 M10,000 55 4.54 0.35 352.1 103.3 104600 1 WM1, 2 1 M10,000 56 118,2010 35 4.54 0.35 352.1 133.0 143600 1 M F SPAH, 1 9 1/2007 56 118,2010 13 0.19 202.5 1530.6 7444440060 1 M F SPAH, 1 9 1/2000 NA 118,2010 13 0.19 202.5 1530.6 744444444 1 M 118,2010 27 0.19 202.5 1350.6 34646444 1 M 118,2010 27 16,300.6 NA 118,2010 27 26 3466444 1 F SPAH, 2 2 108,200.6 26 116,200.6 26 3466444 1 M 118,2010 27 136 3466444 3466444 1 SPAH, 2	1	L		(c t		L			0	0	(inhaled)
Model is a control Model is a contro Model is a control Model i	0 5	~ ~	⊥≥	SPAH, 2 SPAH 3	0L C	6/10/2008	8C NA	21/7/2010	35 43	4.54	0.56	396.2 322 1	1909.8 2260	I adalatiI+ambrisentan TadalafiI+trenrostinil
F SPAH,1 12 21/11/101 19 11/82010 23 6.3 0.43 353.4 2272 M PAH,1 1 9 1/22007 56 11/82010 15 0.19 205.5 15506 M PAH,1 15 1/8/2000 NA 11/8/2010 27 0.19 205.5 15506 F SPAH,1 15 1/8/2000 NA 11/8/2010 27 0.16 305.5 2764 F SPAH,1 5 209/2007 NA 11/8/2010 26 142 305.5 2764 M SPAH,1 5 209/2007 NA 11/8/2010 26 375.9 376.9 376.9 M SPAH,1 15 209/2007 NA 268/2010 26 408 376.9 376.9 376.9 376.9 376.9 376.9 376.9 376.9 376.9 376.9 376.9 366.2 376.9 376.9 366.2 246.8	0 F SPM.1 12 21/1/1001 19 11/8/2010 233 533 2272 15600 Catholocentalisation 11 M PM1.1 12 2002/2008 NA 11/8/2010 13 2002/2008 NA 11/8/2010 13 2025 15600 Sideralisation 12 M PM1.1 5 2008/2008 NA 11/8/2010 13 2019 2025 15600 Sideralisation 13 F SPM1.2 1 10 11/8/2010 24 13 2025 Sideralisation 14 SPM1.2 1 1/1/0/2010 24 38 733 19832 Sideralisation 15 SPM1.1 5 209/2007 73 2926 173 Sideralisation 16 M 11/10/2010 24 282 243 173 267 Sideralisation 16 SPM1.2 1 11/10/2010 24 243 2725 Sideralisation <td>)</td> <td>:</td> <td></td> <td>:</td> <td>0</td> <td>-</td> <td></td> <td>2</td> <td>2</td> <td></td> <td>-</td> <td></td> <td>(inhaled)</td>)	:		:	0	-		2	2		-		(inhaled)
F SPAH,1 9 1/2/2007 56 11/8/2010 18 1.3 0.19 202.5 1530.6 M PAH,1 15 1/8/2000 NA 11/8/2010 17 0.15 0.11 305.5 1175 F SPAH,1 15 1/8/2000 NA 11/8/2010 20 19 305.5 2764 F SPAH,1 5 1/8/2005 NA 11/8/2010 27 156 0.11 305.5 175 F SPAH,1 5 1/8 11/8/2010 27 158 0.17 202.6 2408 M SPAH,2 13 11/10/2001 73 25/8/2010 24 38 1732 F SPAH,2 18 1/31/96 NA 25/8/2010 24 37.3 1963.2 M SPAH,2 18 1/31/9201 24 38 173.2 2692 M SPAH,2 16 17 19/9 0.16 <t< th=""><td>10 F SPAH,1 9 1/2/2007 56 11/8/2010 13 0.19 2/20.5 13/30.6 Glidentifi-unchanthanthanthanthanthanthanthanthanthant</td><td>6</td><td>ш</td><td>SPAH, 1</td><td>12</td><td>21/11/1001</td><td>19</td><td>11/8/2010</td><td>23</td><td>6.3</td><td>0.43</td><td>353.4</td><td>2272</td><td>Ca²⁺ blocker</td></t<>	10 F SPAH,1 9 1/2/2007 56 11/8/2010 13 0.19 2/20.5 13/30.6 Glidentifi-unchanthanthanthanthanthanthanthanthanthant	6	ш	SPAH, 1	12	21/11/1001	19	11/8/2010	23	6.3	0.43	353.4	2272	Ca ²⁺ blocker
M PAH,2 2 2008/3008 NA 11/8/2010 17 0.15 0.11 36.5 175 F SPAH,1 15 1/8/2005 NA 11/8/2010 20 1.9 36.5 2764 F SPAH,1 15 1/8/2005 NA 11/8/2010 26 1.9 36.5 2764 F SPAH,1 5 26/8/2003 38 25/8/2010 24 36.5 2408 F SPAH,1 3 11/10/2001 73 25/8/2010 24 376.9 376.9 386.2 F SPAH,2 13 11/10/2001 73 25/8/2010 24 36.5 27.4 M SPAH,2 13 11/10/2001 73 25/8/2010 24 37.5 376.9 386.2 M SPAH,2 16 1/3 38/2010 24 37.5 36.9 2408 M SPAH,1 16 19/2/1997 NA 4/10/2010 2	N FM-L 2 2008/2068 NA 11/8/2010 17 0.15 0.11 365 175 Sildentifitregrostini (x,) 1 F FM-L 15 1/8/2000 NA 11/8/2010 20 19 363 175 Sildentifitregrostini (x,) 1 F FM-L 15 1/8/2005 NA 11/8/2010 27 14 704 363 175 Sildentifitregrostini (x,) 1 F FM-L 1 3 209/2001 24 343 1732 Gaffitregrostini (x,) 1 F FM-L 15 26/9200 24 343 1732 Gaffitregrostini (x,) 1 F FM-L 16 1/9/1000 24 263 366 Sildentifitregrostini (x,) 1 FM-L 16 1/9/2000 54 14 266 568 37/3 1982 Sildentifitregrostini (x,) 1 FM-L 19/19/2005 70 89/2010 61	10	ш	SPAH, 1	თ	1/2/2007	56	11/8/2010	1	1.3	0.19	202.5	1530.6	Sildenafil+ambrisentan+ Ca ²⁺ hlocker
M IPAH,1 15 1(8)2000 NA 11/8/2010 20 19 0.16 350 2764 F SPAH,2 12 19/5/2005 NA 11/8/2010 27 1.65 0.17 202.6 2408 F SPAH,1 5 26/8/2005 NA 11/8/2010 26 56.8 0.36 33.78 13733 1963.2 F FPAH,1 3 209/2007 NA 25/8/2010 26 142 0.36 33.73 1963.2 M SPAH,2 13 11/10/2001 73 25/8/2010 26 142 0.36 3763 1963.2 M FPAH,1 15 26/10/2005 NA 8/9/2010 61 7.66 0.72 3303 2264 M FPAH,1 15 26/10/2005 NA 8/9/2010 61 7.66 0.72 3303 2264 M FPAH,1 15 19/2/1997 NA 4/10/2010 80	M FM-I IS IR2000 NA I1/82010 20 19 350 2764 Tadalithiopost- animisation 13 F SPAH, I 5 269/2005 NA 11/82010 25 568 0.17 202.60 301 376.9 Iadalithiopost- animisation 14 F SPAH, I 5 269/2007 NA 11/82010 26 568 0.17 202.60 301 376.9 Iadalithiopost- animisation 15 SPAH, I 5 269/2007 78 25/82010 26 142 0.36 376.9 1362.2 Sloner Sloner 16 M PAH, I 15 269/2007 76 142 0.36 376.9 Sloner Slone Sloner Sloner <td>÷</td> <td>Σ</td> <td>IPAH, 2</td> <td>CJ</td> <td>20/08/2008</td> <td>NA</td> <td>11/8/2010</td> <td>17</td> <td>0.15</td> <td>0.11</td> <td>305.5</td> <td>1175</td> <td>Sildenafil+treprostinil (<i>i.v.</i>)</td>	÷	Σ	IPAH, 2	CJ	20/08/2008	NA	11/8/2010	17	0.15	0.11	305.5	1175	Sildenafil+treprostinil (<i>i.v.</i>)
F SPAH, 2 12 19/5/2005 NA 11/8/2010 37 1.65 0.17 202.6 2408 F SPAH, 1 5 26/8/2009 38 25/8/2010 26 6.68 0.17 202.6 2408 F FPAH, 1 5 26/8/2009 38 25/8/2010 26 14.2 0.49 343 1953.2 M SPAH, 2 13 11/10/2001 73 25/8/2010 26 14.2 0.86 376.9 1965.2 M SPAH, 1 15 26/10/2005 NA 8/9/2010 61 7.66 0.72 330.3 2264 M SPAH, 1 15 26/10/2005 NA 4/10/2010 80 4.5 0.36 371.3 1953.2 M SPAH, 2 10 19/12/1995 NA 13/10/2010 74 6.5 0.46 399.5 2414 M SPAH, 2 10 11/11/2004 13/10/2010 74 6.5	1 F SPAH, 2 12 195/2005 NA 11/8/2010 37 165 0.17 202.6 2.408 Stemania 1.4 F SPAH, 1 5 2.68/2000 38 5/6/2010 26 5/6 0.17 202.6 2.408 Stemania 1.4 F SPAH, 1 5 2.69/2007 NA 25/6/2010 26 0.49 343.8 1732 Cat ⁴ -blobeertan 1.6 M SPAH, 2 13 11/10/2001 73 25/6/2010 36 376.9 18662 Clobaria 1.6 M PAH, 1 15 26/10/2001 61 7.66 0.72 330.3 25/6/4 Stemaria 1.6 PAH, 1 17 5 26/10/2001 61 7.66 0.72 330.3 25/6/4 Stemaria 1.6 PAH, 1 17 6 0.72 390.3 241.4 Tatabareana 1.6 PAH, 1 17 8 9/10/2010 <td>12</td> <td>Σ</td> <td>IPAH, 1</td> <td>15</td> <td>1/8/2000</td> <td>NA</td> <td>11/8/2010</td> <td>20</td> <td>1.9</td> <td>0.16</td> <td>350</td> <td>2764</td> <td>Tadalafil+iloprost+</td>	12	Σ	IPAH, 1	15	1/8/2000	NA	11/8/2010	20	1.9	0.16	350	2764	Tadalafil+iloprost+
F SPAH, 2 12 19/5/2005 NA 11/8/2010 37 1.65 0.17 202.6 2408 F SPAH, 1 5 26/8/2003 38 25/8/2010 26 56.8 0.17 202.6 2408 M SPAH, 1 5 26/8/2007 NA 2/5/8/2010 26 14.2 0.36 376.9 1386.2 M SPAH, 2 13 11/10/2001 73 25/8/2010 56 14.2 0.36 376.9 1886.2 M FAH, 1 15 26/10/2005 NA 8/9/2010 61 7.66 0.77 330.3 2244 M FAH, 1 15 26/10/2005 NA 4/10/2010 80 4.5 0.39 343 2692 M FAH, 1 15 26/10/2005 NA 4/10/2010 80 4.5 0.39 343 2692 M FAH, 2 10 17/12/2004 106 13/10/2010 74 6.5<	1 F SPAH, 2 12 195/2005 NA 118/2010 37 165 0.17 202.6 2.408 Sidhandlh-bosentan 1 F SPAH, 1 5 2.68/2005 38 25/8/2010 26 5.88 0.49 343.8 1722 Ca ² blocker 1 F SPAH, 2 13 11/10/201 73 25/8/2010 26 142 0.85 377.3 196.32 Ca ⁴ blocker 1 F SPAH, 2 13 11/10/201 73 25/8/2010 56 142 0.85 377.3 196.32 Sildentill 1 F SPAH, 4 17 192/1997 NA 8/9/2010 61 7/66 0.72 333.3 253.4 Sildentill N+perosinin (N+perosinin (N+perosinin <td></td> <td>ambrisentan</td>													ambrisentan
F SPAH,1 5 26/8/2009 38 25/8/2010 26 6.68 0.49 343.8 1732 F IPAH,1 3 209/2007 NA 25/8/2010 26 1.42 0.36 37.3 1965.2 F IPAH,1 3 209/2007 NA 25/8/2010 56 1.42 0.36 37.3 1963.2 M IPAH,1 15 26/9/2007 NA 8/9/2010 56 1.42 0.36 37.3 1963.2 M IPAH,1 15 26/10/2005 70 8/9/2010 61 7.66 0.72 330.3 2554 M IPAH,1 15 26/10/2005 70 8/9/2010 80 4.5 0.36 343 2692 M SPAH,2 17 19/2/1997 NA 13/10/2010 32 4.5 0.36 343 2692 M SPAH,2 2 2 2 4.5 0.36 310.6 1791.4 <td>14 F SPAH, I 5 268/2009 38 25/8/2010 26 568 0.49 3428 1722 Ca^{**} Diocker 16 M SPAH, I 3 209/2007 NA 25/8/2010 56 142 0.36 3769 1886.2 Sildenalli sildenalli 17 F SPAH, 3 18 1/3/1996 NA 89/2010 61 7.66 0.72 330.3 2254 Sildenalli+reprosini (x)+armbisentan 18 M FAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.72 330.3 2254 Sildenalli+reprosini (x)+armbisentan 19 M FAH, 1 15 26/10/2005 70 89/2010 80 45 0.39 343 2692 Tadali+reprosini (x)+armbisentan 19 M FAH, 1 16 13/10/2010 80 45 0.39 343 2692 Tadali+reprosini (x)+armbisentan 10 FAH, 2 10 17/1/2/2004<td>13</td><td>ш</td><td>SPAH, 2</td><td>12</td><td>19/5/2005</td><td>AN</td><td>11/8/2010</td><td>37</td><td>1.65</td><td>0.17</td><td>202.6</td><td>2408</td><td>Sildenafil+bosentan</td></td>	14 F SPAH, I 5 268/2009 38 25/8/2010 26 568 0.49 3428 1722 Ca ^{**} Diocker 16 M SPAH, I 3 209/2007 NA 25/8/2010 56 142 0.36 3769 1886.2 Sildenalli sildenalli 17 F SPAH, 3 18 1/3/1996 NA 89/2010 61 7.66 0.72 330.3 2254 Sildenalli+reprosini (x)+armbisentan 18 M FAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.72 330.3 2254 Sildenalli+reprosini (x)+armbisentan 19 M FAH, 1 15 26/10/2005 70 89/2010 80 45 0.39 343 2692 Tadali+reprosini (x)+armbisentan 19 M FAH, 1 16 13/10/2010 80 45 0.39 343 2692 Tadali+reprosini (x)+armbisentan 10 FAH, 2 10 17/1/2/2004 <td>13</td> <td>ш</td> <td>SPAH, 2</td> <td>12</td> <td>19/5/2005</td> <td>AN</td> <td>11/8/2010</td> <td>37</td> <td>1.65</td> <td>0.17</td> <td>202.6</td> <td>2408</td> <td>Sildenafil+bosentan</td>	13	ш	SPAH, 2	12	19/5/2005	AN	11/8/2010	37	1.65	0.17	202.6	2408	Sildenafil+bosentan
F IPAH, 1 3 20/9/2007 NA 25/8/2010 24 3.8 0.36 376.9 1886.2 M SPAH, 2 13 11/10/2001 73 25/8/2010 56 14.2 0.36 376.9 1886.2 M IPAH, 1 15 26/10/2005 70 8/9/2010 61 7.66 0.72 330.3 2544 M IPAH, 1 15 26/10/2005 70 8/9/2010 61 7.66 0.72 339.5 2414 M IPAH, 1 15 26/10/2005 70 8/9/2010 80 4.5 0.39 343 2692 M SPAH, 4 17 19/2/1995 NA 13/10/2010 32 4.5 0.39 343 2692 M SPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.046 327.1 1791.4 M SPAH, 2 10 11/12/2004 106 13/10/2010 74 <	15 F IPAH, I 3 200/2007 NA 25/8/2010 24 38 0.36 3759 1866.2 Sildenatii 17 F SPAH, 2 13 11/10/2001 73 25/8/2010 56 14.2 0.86 3733 1963.2 Sildenatii 17 F SPAH, 3 18 1/3/1996 NA 89/2010 61 7.66 0.35 330.3 2254 Sildenatii 18 M IPAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.35 330.3 229.4 Sildenatii 18 M IPAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.32 393.5 2414 IndatiiH-ieposini (u,)+ 10 I772/2004 106 13/10/2010 74 65 0.36 327.1 1791.4 Treposini (u,)+ 26 M FAH, 2 10 1772/2004 106 313/10/2010 74 65	14	ш	SPAH, 1	2	26/8/2009	38	25/8/2010	26	5.68	0.49	343.8	1732	Ca ²⁺ blocker
M SPAH, 2 13 11/10/2001 73 25/8/2010 56 14.2 0.85 377.3 1963.2 R SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 M IPAH, 1 15 26/10/2005 70 8/9/2010 61 7.66 0.72 330.3 2254 M IPAH, 1 15 26/10/2005 70 8/9/2010 61 7.66 0.72 330.3 259.4 M SPAH, 4 17 19/2/1995 NA 13/10/2010 80 4.5 0.39 343 2692 M SPAH, 2 10 17/12/2004 NA 13/10/2010 32 4.5 0.39 343 2692 M IPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.66 327.1 1791.4 M SPAH, 2 2 2 2 2/10/2010 14 0.6	16 M SPAH, 2 13 11/10/2001 73 25/8/2010 56 14.2 0.85 377.3 1963.2 Sildenafil+reprostinil 17 F SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 Sildenafil+reprostinil 18 M FPH, 1 15 26/10/2005 70 8/9/2010 64 5 0.72 330.3 2254 Sildenafil+reprostinil 19 M FPH, 1 15 26/10/2005 70 8/9/2010 84 4.5 0.39 33.3 2264 Sildenafil+reprostinil 19 M FPH, 2 10 17/12/1995 NA 13/10/2010 74 6.5 0.46 327.1 1791.4 Tradatil+reprostinil (w, + 20 M FPH, 2 10 17/1/2/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Tradatil+reprostinil (w, + 21 M FPH, 2	15	ш	IPAH, 1	က	20/9/2007	AN	25/8/2010	24	3.8	0.36	376.9	1886.2	Sildenafil
F SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 M IPAH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 399.5 2414 M IPAH, 1 15 26/10/2005 70 8/9/2010 80 4.5 0.39 343 2692 2414 M SPAH, 2 22 19/2/1995 NA 4/10/2010 80 4.5 0.39 343 2692 2414 M SPAH, 2 19 19/2/1995 NA 13/10/2010 32 4.5 0.39 343 2692 M IPAH, 2 10 17/12/2004 NA 13/10/2010 32 4.5 0.66 327.1 1791.4 M SPAH, 1 1 2 29/0/2008 NA 10/11/2010 28 22 0.66 210.2 1904 M SPAH, 1 1 2 2/10/2008 <td< th=""><td>17 F SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 Sileonalit-reposition (w.)+ambisentan 18 M FPH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 399.5 2414 Tadalit-reposition (w.)+ambisentan 19 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 Tadalit-reposition (w.)+ambisentan 20 M SPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.39 343 2692 Tadalit-reportostenol (w.)+ambisentan 21 M SPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.39 343 2692 Tadalit-reportostenol (w.)+ambisentan 21 M SPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 371 1791.4 Trepostini (w.)+ambisentan <td< td=""><td>16</td><td>Σ</td><td></td><td>13</td><td>11/10/2001</td><td>73</td><td>25/8/2010</td><td>56</td><td>14.2</td><td>0.85</td><td>377.3</td><td>1963.2</td><td>Sildenafil+treprostinil</td></td<></td></td<>	17 F SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 Sileonalit-reposition (w.)+ambisentan 18 M FPH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 399.5 2414 Tadalit-reposition (w.)+ambisentan 19 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 Tadalit-reposition (w.)+ambisentan 20 M SPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.39 343 2692 Tadalit-reportostenol (w.)+ambisentan 21 M SPAH, 2 10 17/12/2004 106 13/10/2010 32 4.5 0.39 343 2692 Tadalit-reportostenol (w.)+ambisentan 21 M SPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 371 1791.4 Trepostini (w.)+ambisentan <td< td=""><td>16</td><td>Σ</td><td></td><td>13</td><td>11/10/2001</td><td>73</td><td>25/8/2010</td><td>56</td><td>14.2</td><td>0.85</td><td>377.3</td><td>1963.2</td><td>Sildenafil+treprostinil</td></td<>	16	Σ		13	11/10/2001	73	25/8/2010	56	14.2	0.85	377.3	1963.2	Sildenafil+treprostinil
F SPAH, 3 18 1/3/1996 NA 8/9/2010 61 7.66 0.72 330.3 2254 M IPAH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 399.5 2414 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2592 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 M SPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 M SPAH, 2 2 29/10/2009 28 21/10/2010 74 6.5 0.66 316.6 1495 M SPAH, 1 1 2 22/12/2008 NA 10/11/2010 28 22.2 0.66 212 1495 M SPAH, 1 1 1 2 2/10/2010 28 <t< th=""><td>17 F SPAH, 3 18 1/3/1996 NA 89/2010 61 7.66 0.72 330.3 2254 Sidenalit-Interposini (u/)+ 18 M FAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.72 330.3 2254 Sidenalit-Interposini (u/)+ 19 M FAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2892 Tadalit-Introporsinol 20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2892 Tadalit-Introporsinol 21 M SPAH, 2 10 13/10/2010 32 4.5 0.66 327.1 1791.4 Tradalit-Introporsinol 21 M SPAH, 2 10 13/10/2010 74 6.5 0.66 327.1 1791.4 Tradaliti-Introporsinol 23 M SPAH, 1 1 2202 1310 10 10</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(i.v.)+ambrisentan</td></t<>	17 F SPAH, 3 18 1/3/1996 NA 89/2010 61 7.66 0.72 330.3 2254 Sidenalit-Interposini (u/)+ 18 M FAH, 1 15 26/10/2005 70 89/2010 61 7.66 0.72 330.3 2254 Sidenalit-Interposini (u/)+ 19 M FAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2892 Tadalit-Introporsinol 20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2892 Tadalit-Introporsinol 21 M SPAH, 2 10 13/10/2010 32 4.5 0.66 327.1 1791.4 Tradalit-Introporsinol 21 M SPAH, 2 10 13/10/2010 74 6.5 0.66 327.1 1791.4 Tradaliti-Introporsinol 23 M SPAH, 1 1 2202 1310 10 10													(i.v.)+ambrisentan
M IPAH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 399.5 2414 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 333.5 2414 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.36 327.1 1791.4 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 M SPAH, 2 2 29/05/2007 20 13/10/2010 74 6.5 0.66 327.1 1791.4 M SPAH, 1 1 2 22010/2005 28 21/10/2010 28 22.2 0.66 212 1495 M SPAH, 1 1 3 8/37.010 NA 10/11/201	18 M IPAH, 1 15 26/10/2005 70 8/9/2010 44 6.2 0.46 39.5 2414 Tadatifi-ambrisantan 19 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 Tadatifi-ambrisantan 20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 Tadatifi-ambrisantan 21 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.46 240.2 1957.2 Ambrisantan 22 M PAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Tradatifi-ambrisantan 23 M SPAH, 2 2 2 0.66 327.1 1791.4 Tradatifi-ambrisantan 24 M SPAH, 1 1 1 2 2/17/2/2004 10/11/2010 14<	17	ш		40	1/3/1996	NA	8/9/2010	61	7.66	0.72	330.3	2254	Sildenafil+treprostini (i.v.)+
M IFAH, I ID Ze/10/2005 /0 69/2010 44 6.2 0.46 395.5 2414 M SPAH, 4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 2414 M SPAH, 2 12 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 2414 M SPAH, 2 22 19/12/1995 NA 13/10/2010 74 6.5 0.39 343 2692 M SPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.46 240.2 1957.2 M SPAH, 2 2 29/05/2007 20 13/10/2010 74 6.5 0.66 327.1 1791.4 M SPAH, 1 1 2 237.10 170 19 10 10 1791.4 10 M SPAH, 1 1 2 2 29/05/2008 NA <td>No IPAH,1 15 26/10/2005 70 89/2010 44 6.2 0.46 539.5 2414 Iadatatitation 20 M SPAH,4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 Tadatatitation 21 M SPAH,2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 Tadatatitation 21 PAH,2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 22 M SPAH,2 2 2 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 23 M SPAH,2 2 2 2 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 23 M SPAH,2 2 2 0.66 327.1 1791.4 Treprosin</td> <td>1</td> <td>2</td> <td></td> <td>L</td> <td></td> <td>C</td> <td>01001010</td> <td></td> <td>0</td> <td>010</td> <td></td> <td></td> <td></td>	No IPAH,1 15 26/10/2005 70 89/2010 44 6.2 0.46 539.5 2414 Iadatatitation 20 M SPAH,4 17 19/2/1997 NA 4/10/2010 80 4.5 0.39 343 2692 Tadatatitation 21 M SPAH,2 22 19/12/1995 NA 13/10/2010 32 4.5 0.39 343 2692 Tadatatitation 21 PAH,2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 22 M SPAH,2 2 2 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 23 M SPAH,2 2 2 2 0.66 327.1 1791.4 Treprosinit (i/v)+bosentan 23 M SPAH,2 2 2 0.66 327.1 1791.4 Treprosin	1	2		L		C	01001010		0	010			
M SPAH, 2 22 19/12/1995 NA 7/02010 00 7.0 0.03 0.04 0.04 0.03 0.04 0.04 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.03 <th0< th=""> 0.04 0.03 0</th0<>	20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.04 240.2 1957.2 Manisentan (u/u)+bosentan 21 M IPAH, 2 10 17/12/1995 NA 13/10/2010 32 4.5 0.046 240.2 1957.2 Ambisentan 21 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprostini (u/u)+ 22 M SPAH, 2 4 29/05/2007 20 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprostini (u/u)+ 23 M SPAH, 2 2 29/10/2009 28 21/10/2010 28 22 0.16 1495 Sidenafil 24 M SPAH, 1 1 1 22/12/2008 Na 10/11/2010 28 212 1495 Sidenafil 25 M SPAH, 1 1 3 8/3/2010 NA 10/11/2010 32 3 0.35 1495 Sidenafil 26	0 0	ΣZ	SDALL A	Ω ¢	2007/01/07		0/0/2010 1/10/0010	44 α	7.0 V	0.40	0.995.0 2.4.2	2602	Tadalalii+amorrotonol Tadalafii amorrotonol
M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.46 240.2 1957.2 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.46 240.2 1957.2 M SPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.46 327.1 1791.4 M SPAH, 2 2 2 29/05/2007 20 13/10/2010 14 0.13 319.6 1904 M SPAH, 1 1 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 M SPAH, 1 1 2 2 2 0.66 0.16 212 1495 M SPAH, 1 3 8/3/2010 NA 10/11/2010 23 3 0.37 1495 M SPAH, 1 11 10 10/11/2010 32 3 0.37 1382.4 </th <td>20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.46 240.2 1957.2 Ambrisentan 21 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprostinil (<i>i</i>, <i>i</i>)+ 22 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 190.4 None 23 M SPAH, 1 1 22 0.24 316.6 1495 Sidenafil 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 22/0 0.16 212 1495 Sidenafil 25 M SPAH, 1 11 10/10/2005 48 10/11/2010 32 3 193.6 Sidenafil 25 M SPAH, 1 11 1 0/11/2010 32 3 0.35 1785.4 Tadalafil+bosentan <t< td=""><td>2</td><td>2</td><td>5</td><td>-</td><td>001</td><td></td><td>0-0-10-17</td><td>3</td><td>2</td><td>0</td><td>5</td><td>1</td><td>(i.v.)+bosentan</td></t<></td>	20 M SPAH, 2 22 19/12/1995 NA 13/10/2010 32 4.5 0.46 240.2 1957.2 Ambrisentan 21 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprostinil (<i>i</i> , <i>i</i>)+ 22 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 190.4 None 23 M SPAH, 1 1 22 0.24 316.6 1495 Sidenafil 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 22/0 0.16 212 1495 Sidenafil 25 M SPAH, 1 11 10/10/2005 48 10/11/2010 32 3 193.6 Sidenafil 25 M SPAH, 1 11 1 0/11/2010 32 3 0.35 1785.4 Tadalafil+bosentan <t< td=""><td>2</td><td>2</td><td>5</td><td>-</td><td>001</td><td></td><td>0-0-10-17</td><td>3</td><td>2</td><td>0</td><td>5</td><td>1</td><td>(i.v.)+bosentan</td></t<>	2	2	5	-	001		0-0-10-17	3	2	0	5	1	(i.v.)+bosentan
M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.13 319.6 1904 M SPAH, 2 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 M SPAH, 1 1 2 22/12/2008 NA 10/11/2010 28 2.2 0.16 212 1495 M SPAH, 1 1 2 22/12/2008 NA 10/11/2010 28 2.2 0.16 212 1495 M SPAH, 1 11 10 10/11/2010 32 3 0.37 382.4 1933.6 M SPAH, 1 11 10 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4	21 M IPAH, 2 10 17/12/2004 106 13/10/2010 74 6.5 0.66 327.1 1791.4 Treprostinil (iv.)+ 22 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.13 319.6 190.4 None 23 M SPAH, 1 1 22 22/10/2009 28 21/10/2010 28 22/10/2008 None 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 22/2 0.24 316.6 1495 Sidenafil 25 M SPAH, 1 1 22/12/2008 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sidenafil 25 M SPAH, 1 11 10/10/2005 48 10/11/2010 32 3 0.37 382.4 1933.6 Sidenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	20	Σ	SPAH, 2	22	19/12/1995	NA	13/10/2010	32	4.5	0.46	240.2	1957.2	Ambrisentan
M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 1904 M SPAH, 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 2.2 0.24 316.6 1495 M SPAH, 1 3 8/3/2010 NA 10/11/2010 28 2.2 0.16 212 1429.8 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	22 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 1904 None 23 M SPAH, 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 Sidenafil 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 2.2 0.24 316.6 1495 Sidenafil 25 M SPAH, 1 1 22/12/2008 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sidenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	21	Σ	IPAH, 2	10	17/12/2004	106	13/10/2010	74	6.5	0.66	327.1	1791.4	Treprostinil (i.v.)+
M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 1904 M SPAH, 2 2 29/10/2009 28 21/10/2010 28 22/10/2016 1495 M SPAH, 1 1 22/12/2008 NA 10/11/2010 19 0.6 0.16 212 1495 M SPAH, 1 3 8/3/2010 NA 10/11/2010 19 0.6 0.16 212 1429.8 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	22 M SPAH, 2 4 29/05/2007 20 13/10/2010 14 0.4 0.13 319.6 1904 None 23 M SPAH, 2 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 Sidenafi 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 28 2.2 0.24 316.6 1495 Sidenafi 25 M SPAH, 1 1 22/12/2008 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sidenafi 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafit-hosentan													tadalafil
M SPAH, 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 M SPAH, 1 1 22/12/2008 NA 10/11/2010 19 0.6 0.16 212 1495 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	23 M SPAH, 2 2 29/10/2009 28 21/10/2010 28 2.2 0.24 316.6 1495 Sildenafil 24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 19 0.6 0.16 212 1429.8 Sildenafil 25 M SPAH, 1 1 22/12/2008 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sildenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 32 3 0.37 382.4 1933.6 Sildenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	22	Σ	SPAH, 2	4	29/05/2007	20	13/10/2010	14	0.4	0.13	319.6	1904	None
M SPAH, 1 1 22/12/2008 NA 10/11/2010 19 0.6 0.16 212 1429.8 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	24 M SPAH, 1 1 22/12/2008 NA 10/11/2010 19 0.6 0.16 212 1429.8 Sildenafil 25 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sildenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	23	Σ	SPAH, 2	0	29/10/2009	28	21/10/2010	28	2.2	0.24	316.6	1495	Sildenafil
M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	25 M SPAH, 1 3 8/3/2010 NA 10/11/2010 32 3 0.37 382.4 1933.6 Sildenafil 26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	24	Σ	SPAH, 1	, -	22/12/2008	NA	10/11/2010	19	0.6	0.16	212	1429.8	Sildenafil
F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4	26 F IPAH, 1 11 10/10/2005 48 10/11/2010 41 4 0.46 293.2 1785.4 Tadalafil+bosentan	25	Σ	SPAH, 1	က	8/3/2010	NA	10/11/2010	32	ი	0.37	382.4	1933.6	Sildenafil
		26	ш	IPAH, 1	7	10/10/2005	48	10/11/2010	41	4	0.46	293.2	1785.4	Tadalafil+bosentan

TABLE	Ŭ E 7	TABLE 2 Control subject data							
	Sex	Diagnosis	Age yrs	Date of diagnosis	Date of sample dav/month/vr	Ĩ.	Fibrocytes	MCP-1 pg·mL ⁻¹	SDF-1 pg·mL ⁻¹
						%	× 10 ⁶ cells·mL ⁻¹		
	Σ	WPW	œ	7/2/2007	14/7/1010	. 	0.13	195.2	1447.6
2	Σ	WPW, closing VSD, no PH	13	25/9/1995	14/7/1010	0.6	0.25	272.4	2236
ю	ш	Arrhythmia (SVT)	10	29/6/2005	14/7/1010	0.9	0.1	267	1672.8
4	ш	Arrhythmia (SVT)	17	21/5/1999	15/7/2010	0.8	0.3	293.1	1702.4
5	Σ	Arrhythmia (SVT)	14	21/3/2002	15/7/2010	0.9	0.13	242.8	1880.2
9	ш	WPW	თ	15/5/2002	21/7/2010	. 	0.32	318.7	2088
7	Σ	Arrhythmia (SVT)	13	7/10/2008	21/7/2010	, -	0.15	273.5	2460
8	Σ	WPW	14	6/10/1992	11/8/2010	0.9	0.1	346.5	2496
6	ш	Arrhythmia (SVT)	17	21/11/2001	11/8/2010	, -	0.32	259.4	1933.6
10	Σ	Arrhythmia (SVT)	14	1/2/2007	11/8/2010	0.3	0.33	302	3084
MCP: mo	onocyte ch	MCP: monocyte chemoattractant protein; SDF: stromal derived factor; M: male; F: female; WPW: Wolff-Parkinson-White syndrome; VSD: ventricular septal defect; PH: pulmonary hypertension; SVT: supraventricular	derived factor; N	<i>A</i> : male; F: female; WPW: V	Volff-Parkinson-White syndi	ome; VSD: ventr	icular septal defect; PH: p	ulmonary hypertension;	SVT: supraventricular
tachycardia	dia.								

Statistical analysis

All values were expressed as mean \pm SEM. Comparison between groups was performed using GraphPad software (GraphPad Software for Science Inc., San Diego, CA, USA). An unpaired t-test was performed for two-group comparisons while a Pearson r correlation coefficient was used to correlate fibrocyte number to clinical and haemodynamic parameters. Statistical significance was defined as p<0.05.

RESULTS

Fibrocyte quantification

Circulating fibrocytes are increased in several chronic inflammatory disorders, including fibrotic lung disease in adults [12]. Furthermore, higher numbers of these cells correlate with disease severity and poor outcome [16]. We hypothesised that children and young adults with severe PH would harbour higher numbers of circulating fibrocytes. Indeed, we found that those with PH had significantly higher numbers and percentages of fibrocytes in peripheral blood compared with controls (mean \pm SD 0.42 \times 10⁶ \pm 0.21×10^6 CD45+ procollagen I+ cells per millilitre ($4.24 \pm 3.06\%$) (n=26) versus $0.21 \times 10^6 \pm 0.10 \times 10^6$ CD45+ procollagen I+ cells per millilitre $(0.84 \pm 0.23\%)$ (n=10), respectively) (figs 1, and 2a and b). No statistically significant differences were observed in fibrocyte numbers among those with IPAH compared with secondary PH. No differences were observed in fibrocyte numbers among females and males with PH. Individuals untreated or undergoing one treatment (Ca²⁺ channel blockers, sildenafil or ambrisentan) had a mean fibrocyte/CD45+ count of 3.35%, while for patients treated with two drugs it was 3.90%, and for patients undergoing three or more treatments it was 5.99%. Patients with the most severe disease were those receiving three or more medications.

Fibrocyte correlation to clinical and haemodynamic parameters


Fibrocyte numbers showed a statistically significant correlation to \bar{P}_{pa} (r=0.575, p<0.05) and increasing age (r=0.354, p<0.05) (fig. 2c–f). No correlations were found between fibrocyte numbers and either sex, 6-min walk distance, plasma brain natriuretic peptide (BNP), N-terminal pro-BNP or duration of treatment (data not shown). We found no statistically significant differences in plasma levels of monocyte chemoattractant protein-1 (305.3 ± 64.7 versus 276.7 ± 39.7 pg·mL⁻¹) or stromal derived factor (SDF)-1 ($1,943.6\pm398.5$ versus $2,100.1\pm459.9$ pg·mL⁻¹) between those with PH versus controls, respectively.

Immunophenotypic confirmation of fibrocytes

We sought to confirm the flow sorting results for fibrocytes from control and PH subjects. Using the same procedures as for flow cytometry, we verified their phenotype by immunofluorescence. As expected, a percentage of cells from PH patients, but not controls, strongly expressed procollagen, thus confirming the efficacy of the cytometry protocol (fig. 3).

DISCUSSION

Based on animal models that implicate fibrocytes in the pathobiology of PH and on human studies demonstrating increased fibrocyte numbers in patients with interstitial lung disease, we tested the hypothesis that fibrocytes would be increased in the circulation of patients with PH. We found a significant enrichment of circulating fibrocytes (defined as CD45+ procollagen+ cells) in patients with PH compared with



control individuals undergoing catheterisation for arrhythmia. In addition, we found a correlation between fibrocyte counts and \bar{P}_{Pa} as well as age. Taken together with previous findings from our group and others of exuberant decoration of fibrocytes in and around pulmonary vessels in a neonatal calf model of hypoxic PH [18, 20], our data here support the notion that the presence of these progenitor cells may contribute to pathological pulmonary vascular remodelling in the setting of inflammation. This is the first demonstration that individuals with PH harbour




FIGURE 1. Representative flow cytometric analysis for circulating CD45+/ procollagen I C-terminal peptide (PICP)+ cells in controls and pulmonary hypertension (PH) patients. a) CD45/Pacific Blue (PB) versus intracellular isotype control/fluorescein isothiocyanate (FITC) analysis on blood from a representative normal subject. This control was used to set the negative gates. b) CD45+/PICP+ cells in normal blood. x axis: procollagen stained with goat anti-rabbit-FITC secondary antibody. c) CD45/PB versus intracellular isotype control/FITC analysis on blood from a patient with PH. This control was used to set the negative gates for the PH sample, same axes as in panel a. d) CD45+/PICP+ cells in PH blood, same axes as in panel b. e) Side scatter (SS) versus forward scatter (FS) analysis of buffy coat cells from the sample in panel d).

increased numbers of circulating fibrocytes, a cell type that has been identified in adults with chronic inflammatory disorders and is associated with poor prognosis, inflammation and tissue remodelling in the lung. Our study might, therefore, represent the first step in understanding the putative pathological roles of fibrocytes in the course of paediatric PH.

The biology of fibrocytes is rapidly coming into sharper focus. Originally described as a leukocyte subpopulation that effected




FIGURE 2. Circulating fibrocytes are enriched in pulmonary hypertension (PH) compared with controls and correlate to mean pulmonary artery pressure (\bar{P}_{pa}) and age. Fibrocyte counts for 10 controls and 26 PH patients were mean ± sp a) 0.84 ± 0.23% versus 4.24 ± 3.06%, and b) 0.21 × 10⁶ ± 0.10 × 10⁶ versus 0.42 × 10⁶ ± 0.21 × 10⁶ CD45+ procollagen I+ cells per millilitre, respectively. Analysis of correlation of fibrocyte c and e) differential and d and f) absolute cell counts in patients with PH to c and d) \bar{P}_{pa} and e and f) age. e) Note that the correlation between age and fibrocytes expressed as a percentage did not reach significance at α =0.05. c) r=0.575, p<0.05; d) r=0.695, p<0.05; e) r=0.354, p>0.05; f) r=0.401, p<0.05. *: p<0.05 versus control.

tissue repair [21], fibrocytes are critically involved in normal wound healing and fibrosis [22]. Their differentiation from precursor cells is complex but may be inhibited by bacterial infection through Toll-like receptor 2 activation [23]. In other contexts, fibrocytes can be differentiated to myofibroblast and adipocyte phenotypes, by transforming growth factor- β [24] and peroxisome proliferator-activated receptor- γ [25], respectively.

Apart from tissue remodelling, fibrocytes have been negatively implicated in chronic inflammatory conditions. Fibrocytes are mobilised from the bone marrow and accumulate in regions of chronic inflammation, perhaps through the SDF-1/CXC chemokine receptor 4 signalling axis [26]. *In vivo*, fibrocytes have been studied in animal models of PH, and are associated with vascular remodelling, elevated pulmonary artery pressures and




FIGURE 3. Immunofluorescent analysis of circulating fibrocytes. Equivalent numbers of cytospun buffy coat cells were examined from a) controls and b) individuals with pulmonary hypertension for expression of procollagen I N-terminal peptide (PINP) stained with Alexa488 (Invitrogen, Carlsbad, CA, USA) (arrows). Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI).

accumulation in bronchovascular regions [4, 18]. Although the extent of monocytic cell influx into the lung has been well documented in adults with PH [27], ours is the first study to quantitatively assess circulating fibrocytes in children and young adults with PH. The present study has confirmed that fibrocytes are present in the blood of patients with PH. How (or whether) fibrocytes contribute to the remodelling of pulmonary vessels in the human condition remains to be determined. A more precise functional characterisation of fibrocytes, at least in the clinical setting, is currently hampered by the seeming requirement of (intracellular) collagen as the "gold standard" for fibrocyte identification. Magnetic bead or flow sorting using extracellular markers as surrogates for the expression of collagen would obviate the need for fixation and permeabilisation of putative fibrocytes, a process incompatible with many downstream functional assays. Recently, fibrocytes isolated from patients with chronic inflammation have been shown to display an activated phenotype [28]. Additionally, the expression profile for cultured fibrocytes is distinct from monocytes, macrophages and fibroblasts [29]. These findings highlight the complexity of fibrocyte differentiation, the details of which (stem cell, process, temporal mechanics, tissue influence, etc.) remain shrouded in obscurity. Identification of cell surface markers with a high specificity for fibrocytes will facilitate studies designed to understand the functional roles of fibrocytes in vivo, as has already been established for serum amyloid P [30]. Our group has previously shown that vascular remodelling and inflammation of the rat pulmonary vasculature during hypoxia requires circulating cells of a monocytic/macrophage lineage [13]. Use of fibrocyte-specific agonists and antagonists, based on in vitro and in vivo immunophenotyping of surface markers, will more sharply define the cell type most responsible for the remodelling.

Correlation analysis between fibrocyte numbers and \bar{P}_{Pa} and increasing age showed a weak but positive relationship.

Fibrocyte counts did not correlate with other patient demographic data. The lack of a stronger correlative relationship between fibrocyte count and \bar{P}_{pa} is not altogether surprising for several reasons. First, the age range of our PH patient cohort spanned 22 yrs and there was a large standard deviation (6.18 yrs). There are no studies available that define a link between fibrocyte counts and age. We assumed a priori that (young) individuals in the control group would have low fibrocyte numbers ($\leq 1\%$ of total white blood cells), as is observed in control adults. However, this is an assumption that needs additional testing. In any case, we found low numbers of fibrocytes in peripheral blood of controls, numbers similar to those documented in older controls [16]. Secondly, many of the PH patients in our study are on significantly long-standing and varied treatment regimens, including calcium channel blockers, endothelin receptor antagonists, phosphodiesterase inhibitors and prostanoids. In addition, some of the children responded to acute vasodilator challenge and others did not. As such, the variable clinical presentation and underlying pathobiology (e.g. IPAH versus APAH-CHD) of our study group probably reduced the power of fibrocyte number to more closely correlate with severity of PH as measured by \bar{P}_{pa} . In fact, it remains possible that, since treatments with prostacyclin agonists appear to increase the number of late EPCs, such treatment could also lead to mobilisation of fibrocytes into the circulation. In future studies, restricting the analysis of circulating fibrocytes to exclude patients with PH not associated with extensive lung inflammation and remodelling will probably prove fruitful, as will studying patients at diagnosis (untreated patients). Fibrocytes are involved in both normal wound healing and inflammation but at present we are unable to say which of these mechanisms is involved in these patients. We speculate that the mechanism is pro-inflammatory and, perhaps, the data that the patients with the most severe disease (on triple therapy) also have the highest fibrocyte numbers offers a clue in support of this assumption.

This is in contrast to EPCs, which are thought to be decreased with increased severity of PH [4, 5]. It is thus plausible that the collective contributions of distinct progenitor cell populations govern lung homeostasis, and by extension, deviation from homeostasis during pathogenesis.

In conclusion, we have shown quantitative differences in circulating fibrocytes between individuals with PH and those without PH. Fibrocyte count correlated with increased \bar{P}_{pa} and age. This study suggests a potential role for these cells in the pathogenesis of PH, but more studies are needed to confirm our findings. A great deal of renewed research emphasis over the past decade has been placed on mechanisms of lung inflammation and vascular remodelling in PH. Our study points to the potential contributions of circulating mesenchymal progenitors to those inflammatory processes.

SUPPORT STATEMENT

This study was funded by National Institutes of Health (NIH) Specialized Centers of Clinically Oriented Research grant HL-084923-02, NIH Program Project Grant HL-014985-35, NIH/NCRR Colorado CTSI grant number UL1 RR025780, the Jayden DeLuca Foundation and the Leah Bult Pulmonary Hypertension Research Fund.

STATEMENT OF INTEREST

A statement of interest for M.E. Yeager can be found at www.erj. ersjournals.com/site/misc/statements.xhtml

ACKNOWLEDGEMENTS

We would like to especially acknowledge the generosity and kindness of R. Strieter (Robert M. Byrne Cardiovascular Research Center, University of Virgina, Charlottesville, VA, USA) in whose laboratory we learned the techniques used in this report. We also wish to thank M. Burdick from the Strieter laboratory for teaching and graciously hosting us. We thank the University of Colorado Cancer Center Flow Cytometry Core (Denver, CO, USA) for technical assistance.

REFERENCES

- 1 Humbert M. Update in pulmonary hypertension 2008. *Am J Respir Crit Care Med* 2009; 179: 650–656.
- 2 Barst RJ, Ertel SJ, Beghetti M, et al. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011; 37: 1–13.
- 3 Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20–S31.
- **4** Toshner M, Voswinckel R, Southwood M, *et al.* Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2009; 180: 780–787.
- **5** Junhui Z, Xingxiang W, Guosheng F, *et al.* Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. *Respir Med* 2008; 102: 1073–1079.
- 6 Smadja DM, Mauge L, Gaussem P, *et al.* Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. *Angiogenesis* 2010; 14: 17–27.
- 7 Asosingh K, Aldred MA, Vasanji A, et al. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008; 172: 615–627.
- 8 Diller GP, van Eijl S, Okonko DO, *et al*. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. *Circulation* 2008; 117: 3020–3030.
- **9** Hall S, Brogan P, Haworth SG, *et al.* Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. *Thorax* 2009; 64: 778–783.

- **10** Gambaryan N, Perros F, Montani D, *et al.* Targeting of c-kit+ hematopoietic progenitor cells prevents hypoxic pulmonary hypertension. *Eur Respir J* 2011; 37: 1392–1399.
- **11** Davie NJ, Crossno JT Jr, Frid MG, *et al.* Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. *Am J Physiol Lung Cell Mol Physiol* 2004; 286: L668–L678.
- **12** Stenmark KR, Frid MG, Yeager ME. Fibrocytes: potential new therapeutic targets for pulmonary hypertension? *Eur Respir J* 2010; 36: 1232–1235.
- **13** Frid MG, Brunetti JA, Burke DL, *et al.* Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. *Am J Pathol* 2006; 168: 659–669.
- 14 Sun L, Louie MC, Vannella KM, et al. New concepts of IL-10 induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/ CCR2 axis. Am J Physiol Lung Cell Mol Physiol 2010; 300: L341–L353.
- **15** Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. *Int J Biochem Cell Biol* 2010; 42: 535–542.
- **16** Moeller A, Gilpin SE, Ask K, *et al.* Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2009; 179: 588–594.
- 17 Lama VN, Phan SH. The extrapulmonary origin of fibroblasts: stem / progenitor cells and beyond. *Proc Am Thorac Soc* 2006; 3: 373–376.
- **18** Nikam VS, Schermuly RT, Dumitrascu R, *et al.* Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. *Eur Respir J* 2010; 36: 1302–1314.
- **19** Mathai SK, Gulati M, Peng X, *et al.* Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. *Lab Invest* 2010; 90: 812–823.
- **20** Frid MG, Li M, Gnanasekharan M, *et al.* Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall. *Am J Physiol Lung Cell Mol Physiol* 2009; 297: L1059–L1072.
- **21** Bucala R, Spiegel LA, Chesney J, *et al.* Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol Med* 1994; 1: 71–81.
- **22** Bellini A, Mattoli S. The role of the fibrocyte, a bone marrowderived mesenchymal progenitor, in reactive and reparative fibroses. *Lab Invest* 2007; 87: 858–870.
- **23** Maharjan AS, Pilling D, Gomer RH. Toll-like receptor 2 agonists inhibit human fibrocyte differentiation. *Fibrogenesis Tissue Repair* 2010; 3: 23.
- 24 Wang CH, Huang CD, Lin HC, *et al.* Increased circulating fibrocytes in asthma with chronic airflow obstruction. *Am J Respir Crit Care Med* 2008; 178: 583–591.
- **25** Hong KM, Belperio JA, Keane MP, *et al.* Differentiation of human circulating fibrocytes as mediated by transforming growth factor-β and peroxisome proliferator-activated receptor gamma. *J Biol Chem* 2007; 282: 22910–22920.
- **26** Song JS, Kang CM, Kang HH, *et al.* Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. *Exp Mol Med* 2010; 42: 465–472.
- **27** Stenmark KR, Davie NJ, Reeves JT, *et al*. Hypoxia, leukocytes, and the pulmonary circulation. *J Appl Physiol* 2005; 98: 715–721.
- **28** Galligan CL, Siminovitch KA, Keystone EC, *et al.* Fibrocyte activation in rheumatoid arthritis. *Rheumatology (Oxford)* 2010; 49: 640–651.
- **29** Pilling D, Fan T, Huang D, *et al.* Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. *PLoS One* 2009; 4: e7475.
- **30** Pilling D, Roife D, Wang M, *et al*. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. *J Immunol* 2007; 179: 4035–4044.